When compared with other countries, Germany’s provision of palliative care still leaves much to be desired; sustained commitment towards research in palliative care would be an important step towards addressing such shortcomings.

The aim of palliative care is to achieve or maintain the best possible quality of life for patients, their families and relatives in the face of life-threatening, incurable conditions. ‘Palliative care’ is used here as a generic term for any activities involving such individuals. The prevention and relief of suffering are key priorities. A prerequisite of this is the early recognition and accurate recording of all impairments, symptoms and areas of conflict at all physical, mental, social and spiritual levels.

In recent years, public discussion about the topic of life and death has gained in importance. In surveys, 54 percent of respondents reported having contemplated their own mortality. Thirty-nine percent claimed that the topic of life and death was an important or very important concern for members of their immediate circle.
The most common causes of death in Germany are cardiovascular disease and cancer, which account for more than 500,000 fatalities every year. Most of these afflicted people spend their final days suffering from physical symptoms such as pain or dyspnoea, and both they and their families can also be burdened with psychosocial or spiritual problems.

Patients with other severe diseases, such as neurological disorders (Parkinson’s disease, dementia, multiple sclerosis, etc.) and lung diseases, as well as frail, older patients with a range of medical conditions, also require palliative care. Children and adolescents need special care depending on their developmental stage, on the prevailing spectrum of diseases and on their family circumstances.

There is also conjecture about the efficiency of palliative care, since health care research in this area is still in its early days, and there is a substantial need for studies focused on the field of palliative medicine. This statement will make recommendations about what has to be done in the light of both the need to catch up and the perceptible additional demands the future will bring.

These recommendations take into account the irrefutable entitlement we have to the best possible quality of life, and the specific care required by critically and terminally ill patients.

The statement makes three basic recommendations for the provision of:

1. a homogeneous, comprehensive level of high-quality care throughout Germany, which – in contrast to the present situation – is accessible to all those in need;
2. a commitment by every region in Germany to meet in full the actual costs of science-based palliative care in hospitals, care facilities and the home environment;
3. a package of care, scientifically proven and available to all those in need of it in Germany.

This will necessitate the ongoing development of a body of evidence supporting the provision of palliative care in Germany.

Palliative care in Germany should attain at least the same level of excellence as is achieved by global leaders in the field (such as the USA, Great Britain and Sweden). This will require a paradigm shift so that palliative care becomes a science-based discipline, and a concomitant guarantee that appropriate support will be provided for research in palliative medicine.

Ensuring care provision and healthcare research should extend beyond palliative care for cancer patients. Explicit efforts should also be made to improve palliative care in the long term for patients with other medical conditions: those with multimorbidity, dementia and disabilities, patients from all age groups and social situations, care home residents, prison inmates, or the homeless.

Thus, in addition to the recommendation that a basic knowledge of palliative care should become an integral part of initial and advanced training courses for all professional groups involved in the area of palliative care, and that a reliable regulatory framework should be established for the voluntary sector, the following individual recommendations are formulated:
Recommendations

**Recommendation 1:**
The development of an independent national palliative strategy

The strategy should incorporate:
- the nationwide standardisation of regulatory requirements for evidence-based palliative care, in order to ensure the provision of comprehensive, high-quality care throughout Germany;
- the establishment of a research agenda for palliative care;
- the development of nationally consistent quality assurance standards in palliative care based on research results (e.g. as a national palliative register);
- the integration of palliative care into the development of the National Cancer Plan, the National Dementia Strategy, the National Health Care Guidelines, the Disease Management Programme (DMP), and care strategies for other medical conditions.

**Studies on the current and future role of medical technology in maintaining the autonomy and independence of palliative patients, and on how to counterbalance to some extent the anticipated, demographically caused care deficit.**

**Improving palliative medicine by carrying out basic research on systemic biological changes at the end of life and where chronic medical conditions have progressed to the terminal stage.**

**Recommendation 3:**
Promoting the structures for interdisciplinary palliative health care research

Grants aimed specifically at young researchers to provide the necessary incentives to attract them to inter- or transdisciplinary projects.

The development of time-limited interdisciplinary research structures involving clinical scientists and basic researchers, as well as researchers in the fields of palliative nursing care and spiritual and psychosocial studies.

**Recommendation 4:**
Involving patients and their families in decision-making on the drawing-up of a research agenda

The involvement of patients and their families in the development of the research agenda for palliative care is essential if their palliative care needs are to be met. Their input, where appropriate, should serve to make palliative care more responsive to the needs of the recipient.

Intervention studies with endpoints on issues relating to palliative medicine, with the aim of ensuring that a sufficient body of evidence exists on which to base guidelines concerning patient care.
Members of the working group:

**Spokespersons:** Lukas Radbruch (Chair in Palliative Medicine, Faculty of Medicine, University of Bonn), Hans-Peter Zenner (Ear, Nose and Throat Clinic at the Eberhard Karls University Tübingen)

**Members of the working group:** Klaus Auernhammer (Palliative ward, Marienhaus, St. Elisabeth’s Hospital, Saarbrücken), Georg Ertl (Medical Clinic and Polyclinic I, Julius Maximilian University of Würzburg), Dominik Gross (Institute for the History, Theory and Ethics of Medicine, Uniklinik RWTH Aachen), Michael Hallek (Clinic I for Internal Medicine, Cologne University Hospital), Gerhard Höver (Chair in Moral Theology, University of Bonn), Ferdinand Hucho (Institute of Chemistry and Biochemistry, Freie Universität Berlin), Saskia Jünger (Institute for General Practice, Hannover Medical School), Martina Kern (Centre for Palliative Medicine, Malteser Hospital, Bonn/Rhein-Sieg), Ulrich R. Kleeberg (Haematology and Oncology Practice, Altona (HOPA), Struensee-Haus Day Clinic, Hamburg), Volker Lipp (Chair in Civil Law, Law of Civil Procedure, Medical Law and Comparative Law, Georg-August-Universität Göttingen), Friedemann Nauck (Department of Palliative Medicine, University Medical Center Göttingen), Thomas Norgall (Fraunhofer Institute for Integrated Circuits (IIS), Erlangen), Jürgen Osterbrink (Institute of Nursing Science, Paracelsus Private Medical University, Salzburg, Austria), Christoph O斯塔the (Palliative Medicine Centre in the Department of Anaesthesiology, Universitätsklinikum Erlangen), Klaus-Maria Perrar (Centre for Palliative Medicine, Cologne University Hospital), Holger Pfaff (Institute of Medical Sociology, Health Services Research, and Rehabilitation Science (IMVR), University of Cologne), Mathias Pfisterer (Centre for Geriatrics, Agaplesion St Elizabeth Foundation, Darmstadt), Jan Schildmann (Institute of Medical Ethics and the History of Medicine, Ruhr-Universität Bochum), Thomas Schmitz-Rode (Institute of Biomedical Technologies (Helmholtz Institute), Uniklinik RWTH Aachen), Nils Schneider (Institute for General Practice, Hannover Medical School), Werner Schneider (Chair in Sociology, Faculty of Philosophy and Social Sciences, Augsburg University), Rolf-Detlef Treede (Chair in Neurophysiology, Centre for Biomedicine and Medical Technology, Faculty of Medicine of the University of Heidelberg, Mannheim), Boris Zernikow (Institute of Children’s Pain Therapy and Paediatric Palliative Care, Children’s and Adolescents’ Hospital, Datteln)

**Scientific advisors for the working group:** Felix Grützner (Chair in Palliative Medicine, Faculty of Medicine, University of Bonn), Kathrin Happe (German National Academy of Sciences Leopoldina)

**Contact:**
Dr Kathrin Happe
German National Academy of Sciences Leopoldina
Department Science – Policy – Society (Head of department: Elmar König)
politikberatung@leopoldina.org
Phone: +49 (0)345 472 39-867

The German National Academy of Sciences Leopoldina, acatech – National Academy of Science and Engineering, and the Union of the German Academies of Sciences and Humanities provide policymakers and society with independent, science-based advice on issues of crucial importance for our future. The Academies’ members are outstanding researchers from Germany and abroad. Working in interdisciplinary working groups, they draft statements that are published in the series of papers *Schriftenreihe zur wissenschaftsbasierten Politikberatung* (Monograph Series on Science-based Policy Advice) after being externally reviewed and subsequently approved by the Standing Committee of the German National Academy of Sciences Leopoldina.